Experiences with a Failure Investigation Program for Apheresis Blood Products

Faye Kugele
MS, MT(ASCP)SBB, CQM(ASQ)

Process Design - Product QC Principal Associate, American Red Cross

AGENDA

- Apheresis Program Overview
- Sources of Product Quality Failures
- Product QC Program Essential Components
- Monthly Quality Control Monitoring
- Conducting a QC Failure Investigation
- Product Quality Communications
- QC Testing Challenges

Apheresis Program - Overview

The American Red Cross has 262 registered facilities that collect and distribute approximately 630,000 Apheresis Platelets, 321,000 Apheresis Red Cells, and 1,000 Granulocytes annually.

Fenwal

- ALYX: leukoreduced double red cells
- Amicus: leukoreduced platelets (single, double, triples), concurrent plasma
- Autopheresis-C: plasma
- CS3000: granulocytes

Gambro

- Spectra: leukoreduced platelets (single, double), concurrent plasma, granulocytes
- **Trima:** leukoreduced platelets (single, double, triples); concurrent plasma, concurrent non-leukoreduced apheresis red cells

Haemonetics

MCS+ LN8150: leukoreduced double red cells

Apheresis Program – Product QC Testing

The volume of product QC testing performed within the American Red Cross:

- Apheresis Red Cells
 - > 100,000 per year for component hemoglobin and mean total component hemoglobin
 - > 3,200 per year for residual leukocyte counts and percent recovery
- Apheresis Platelets (Platelets pheresis)
 - > 30,000 per year for pH and platelet yield
 - > 4,000 per year for residual leukocyte counts

Apheresis Program – Product QC Testing

Average results - Apheresis Red Cells

- Mean total component hemoglobin
 - Trima 66 g
 - Haemonetics 832F 53 g
 - ALYX 57 g
- Residual leukocyte counts
 - ALYX 99% < 3.5X10⁵
 - Haemonetics 94% < 3.5X10⁵

Apheresis Program – Product QC Testing

Average results - Apheresis Platelets

- pH = 7.4 ± 0.2
- Volume = 255 ± 69 mLs
- Platelet concentration = 1545 X10³ ± 255
- Platelet yield = $3.8 \times 10^{11} + 0.6$

Sources of Product Quality Failures

Failures can be discovered:

- During validation of equipment or process control
- During routine processing
- Result of a customer complaint
- Result of product QC testing

Sources of Product Quality Failures - Examples

During validation of equipment or process control

- New technology introduced
- Additional testing outside of the validation process – such as QC testing at the time of distribution

Sources of Product Quality Failures - Examples

During routine processing

- Collection process
- Manufacturing Process
- Routine QC
- Multiple processes or technology at one site

Sources of Product Quality Failures - Examples

Result of a customer complaint

- Platelets implicated in adverse reaction
- Hemolyzed RBCs

Tracking: Regional Monthly Schedule for Finished Product QC

- Type of product to be tested
- Apheresis instrument type
- Specific site location, as applicable
- Number of collected products (per site)
- Number of product to be tested (per site)

Clear Procedures

Ongoing Monitoring

Process for Failure Investigation and Corrective Actions

Responsibility and Accountability

- Maintaining the Regional Monthly Schedule for Finished Product Quality Control
- Tracking and trending Product Quality Control results
- Notifying key staff when monthly Quality Control fails
- Compiling and initiating the Product QC Summary reports
- Routing the QC Summary reports and data for review
- Reviewing the QC Summary Data

Reviews and Documentation

Review QC forms for:

- Transcription of test results from analyzer printouts
- Completeness of the form
- Correctness of any calculations
- Correctness of any interpretations

If a failure on an individual product:

- Staff notify the supervisor
- Staff conduct an evaluation
- Product suitability for release is evaluated

Monthly Quality Control Monitoring

Routine review of monthly QC reports ensures:

- An adequate number of products are sampled and tested
- The QC results meet or exceed the acceptability criteria
- Track and trend results to include process improvement opportunity where possible

Standardized Failure Investigation

- Accuracy of the sample tested
- Accuracy of the test result
- Process related critical control points

ACTION	Performed	Record Results, if applicable	Initials and Date, if performed	Further Corrective Action	
Quality Control Laboratory					
Was the product tagged for Machine QC, %, or R1? (if so, no further action is necessary)					
Repeat calculations					
Verify Sample Integrity					
Presence of clots					
Presence of hemolysis					
Was sample collected appropriately?					
Verify the following equipment is functioning properly:					
Scale					
QC performed with passing results					
Verify that correct tare bag was used					
Recheck weights and/or confirm weights from other documents					
Verify that segments are removed from RBC bag before weight measurement was taken					
Automated Hematology Analyzer					
QC performed with passing results					
Review maintenance/PM stickers					
Check reagents					
Perform electronic & mechanical checks					
Clean instrument/check waste					
Troubleshoot equipment as necessary					
Document maintenance performed					
Collections Equipment					
[Region Defined]					

Individual Product Quality Control Failure

Product Safety and Risk Evaluation – Product Disposition

- Released as non-standard product code
- Released as another product type
- Released through the Material Review Board process – medical exceptions
- Discarded

Investigation

When a monthly QC failure occurs, actions include:

- Review of the individual product failure checklist(s)
- Look at historical results
- Look at previous failures

Investigation (cont'd.)

- Critical components of the process
 - Procedures
 - Equipment
 - Supplies
- Observe staff
- Other environmental/facility

Investigation Evaluation

- Information gathering
 - Data
 - Observations and interviews
 - Brainstorming, etc.
- Root cause / failure mode analysis
- Isolated vs. process failures

Actions Outside of the Investigation

Product Safety and Risk Evaluation

- Impact to the individual product only
- Scope of impact to time and product type
- Potential risk to a potential recipient

Actions Outside of the Investigation

Regulatory Actions

- Blood Product Deviation Report
- Recall of product(s)
- Limit or cease production
- Other reporting requirements...

Investigation Documentation

- Must stand on its own
 - Over time
 - Independent of audience
 - Be clear and concise

- Must include key information
 - What happened
 - What actions were taken
 - Why
- Follow-up with outcomes of actions

Effectiveness Check

- Perform additional testing if changes are made to process, procedure or training
- Review by the Quality Assurance Department and Medical Director for impact
- Reinstate routine QC testing
- Ensure standard operating procedures are revised to reflect any changes, if applicable

What Happens When You Can Not Determine the Cause...

?

When is testing of additional samples needed...

- Gather additional data
- To confirm actions taken are effective

Product Quality Communications

Communication

- For Failures:
 - To affected staff change or enhancement in a process, procedure, or training
 - To affected staff discuss investigations of failed product QC
 - Supplier, customer (as applicable) discuss failure investigation and outcome
 - To FDA as appropriate
- For Routine Product QC Outcomes
 - Internally and externally- share information regarding product quality data
 - Discuss potential process improvement opportunities

QC Testing Challenges

- Sampling Criteria and Random Sampling
 - representative sampling
- Timing constraints
- Requirements carried over from one product type or technology to another

Tracking	Reviews and Documentation	Ongoing Monitoring	Investigation
Corrective Actions	Clear Procedures	Responsibility Accountability	Communication
Standardized Failure Investigation	Product Safety	Effectiveness Check	Regulatory Actions